IBDEI11W ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18527,1,5,0)
 ;;=5^200.28
 ;;^UTILITY(U,$J,358.3,18527,2)
 ;;=^267365
 ;;^UTILITY(U,$J,358.3,18528,0)
 ;;=201.68^^102^1191^3
 ;;^UTILITY(U,$J,358.3,18528,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18528,1,4,0)
 ;;=4^HODGKINS DIS MIXED CELLULARITY
 ;;^UTILITY(U,$J,358.3,18528,1,5,0)
 ;;=5^201.68
 ;;^UTILITY(U,$J,358.3,18528,2)
 ;;=^267421
 ;;^UTILITY(U,$J,358.3,18529,0)
 ;;=201.58^^102^1191^4
 ;;^UTILITY(U,$J,358.3,18529,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18529,1,4,0)
 ;;=4^HODGKINS DIS NODULAR SCLEROSIS
 ;;^UTILITY(U,$J,358.3,18529,1,5,0)
 ;;=5^201.58
 ;;^UTILITY(U,$J,358.3,18529,2)
 ;;=^267413
 ;;^UTILITY(U,$J,358.3,18530,0)
 ;;=201.18^^102^1191^5
 ;;^UTILITY(U,$J,358.3,18530,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18530,1,4,0)
 ;;=4^HODGKINS GRANULOMA
 ;;^UTILITY(U,$J,358.3,18530,1,5,0)
 ;;=5^201.18
 ;;^UTILITY(U,$J,358.3,18530,2)
 ;;=^267389
 ;;^UTILITY(U,$J,358.3,18531,0)
 ;;=201.48^^102^1191^6
 ;;^UTILITY(U,$J,358.3,18531,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18531,1,4,0)
 ;;=4^HODGKINS LYMPH-HIST PREDOMINAN
 ;;^UTILITY(U,$J,358.3,18531,1,5,0)
 ;;=5^201.48
 ;;^UTILITY(U,$J,358.3,18531,2)
 ;;=^267405
 ;;^UTILITY(U,$J,358.3,18532,0)
 ;;=201.78^^102^1191^7
 ;;^UTILITY(U,$J,358.3,18532,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18532,1,4,0)
 ;;=4^HODGKINS LYMPHOCYTIC DEPLETION
 ;;^UTILITY(U,$J,358.3,18532,1,5,0)
 ;;=5^201.78
 ;;^UTILITY(U,$J,358.3,18532,2)
 ;;=^267429
 ;;^UTILITY(U,$J,358.3,18533,0)
 ;;=201.08^^102^1191^8
 ;;^UTILITY(U,$J,358.3,18533,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18533,1,4,0)
 ;;=4^HODGKINS PARAGRANULOMA NODES
 ;;^UTILITY(U,$J,358.3,18533,1,5,0)
 ;;=5^201.08
 ;;^UTILITY(U,$J,358.3,18533,2)
 ;;=^267381
 ;;^UTILITY(U,$J,358.3,18534,0)
 ;;=201.28^^102^1191^9
 ;;^UTILITY(U,$J,358.3,18534,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18534,1,4,0)
 ;;=4^HODGKINS SARCOMA
 ;;^UTILITY(U,$J,358.3,18534,1,5,0)
 ;;=5^201.28
 ;;^UTILITY(U,$J,358.3,18534,2)
 ;;=^267397
 ;;^UTILITY(U,$J,358.3,18535,0)
 ;;=203.82^^102^1191^10
 ;;^UTILITY(U,$J,358.3,18535,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18535,1,4,0)
 ;;=4^IMMUNOPROLIF NEOPL RELAPSE
 ;;^UTILITY(U,$J,358.3,18535,1,5,0)
 ;;=5^203.82
 ;;^UTILITY(U,$J,358.3,18535,2)
 ;;=^336464
 ;;^UTILITY(U,$J,358.3,18536,0)
 ;;=203.81^^102^1191^11
 ;;^UTILITY(U,$J,358.3,18536,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18536,1,4,0)
 ;;=4^IMMUNOPROLIF NEOPL REMISSION
 ;;^UTILITY(U,$J,358.3,18536,1,5,0)
 ;;=5^203.81
 ;;^UTILITY(U,$J,358.3,18536,2)
 ;;=^267520
 ;;^UTILITY(U,$J,358.3,18537,0)
 ;;=202.58^^102^1191^12
 ;;^UTILITY(U,$J,358.3,18537,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18537,1,4,0)
 ;;=4^LETTERER-SIWE DISEASE
 ;;^UTILITY(U,$J,358.3,18537,1,5,0)
 ;;=5^202.58
 ;;^UTILITY(U,$J,358.3,18537,2)
 ;;=^267487
 ;;^UTILITY(U,$J,358.3,18538,0)
 ;;=202.48^^102^1191^13
 ;;^UTILITY(U,$J,358.3,18538,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18538,1,4,0)
 ;;=4^LEUKEMIC RETICULOENDOTHELIOSIS
 ;;^UTILITY(U,$J,358.3,18538,1,5,0)
 ;;=5^202.48
 ;;^UTILITY(U,$J,358.3,18538,2)
 ;;=^341476
 ;;^UTILITY(U,$J,358.3,18539,0)
 ;;=200.78^^102^1191^14
 ;;^UTILITY(U,$J,358.3,18539,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18539,1,4,0)
 ;;=4^LG CELL LYMPHOMA NODES MULTI
 ;;^UTILITY(U,$J,358.3,18539,1,5,0)
 ;;=5^200.78
 ;;^UTILITY(U,$J,358.3,18539,2)
 ;;=^335228
 ;;^UTILITY(U,$J,358.3,18540,0)
 ;;=204.01^^102^1191^16
 ;;^UTILITY(U,$J,358.3,18540,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18540,1,4,0)
 ;;=4^LYMPHOID LEUK AC,REMISSION
 ;;^UTILITY(U,$J,358.3,18540,1,5,0)
 ;;=5^204.01
 ;;^UTILITY(U,$J,358.3,18540,2)
 ;;=^267522
 ;;
 ;;$END ROU IBDEI11W
